Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 02, 2022

Effective Tumor Debulking With Ibrutinib Lead-In Before Venetoclax Initiation in CLL

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Effective Tumor Debulking With Ibrutinib Before Initiation of Venetoclax: Results From the CAPTIVATE Minimal Residual Disease (MRD) and Fixed-Duration (FD) Cohorts
Clin. Cancer Res 2022 Aug 08;[EPub Ahead of Print], PM Barr, A Tedeschi, WG Wierda, JN Allan, P Ghia, D Vallisa, R Jacobs, S O'Brien, AP Grigg, P Walker, C Zhou, J Ninomoto, G Krigsfeld, CS Tam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading